<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 107 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page106.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=107">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 107 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 107</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=107"><img src="../thumb/107.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>76 / 2020-04                                                  Musculo-Skeletal Agents - 4.1.3 / 4.2 / 4.3
   tan.reacts.which may be fatal, pre-exist.signific.ren.funct.impairm./   Contraindications: Prev.ser.adverse effs., lactat., childr.except those   Hyperuricaem.assoc.with leukaem: Init.200 mg 3xdly.com-
   uncompensat. HF/hypertens./liv.cirrhos., monit. ren./ hepat./card.  with malign., ac.gout, concom.chlorpropamide.  menc.2-3 days bef.ther.adjust.to maint.dos.300-400 mg dly. Childr:
   funct.& discont.if deteriorat. detect., dehydrat., adeq.hydrat., new   Side effects: Skin & bld.hypersens. reacts., fev., chills, malaise,   8 mg/kg bm dly.
   onset/recur. CHF, CF hist., L.ventric.dysfunct., hypertens., pre-exist.   musc.ache, arthralg., vasculit., periph.neurit., bone marr. depress.,   Contraindications: Lactat., childr.(except.with malign.).
   oed., comprom.card.funct., monit.BP consid. alt. ther.if signif.rise,   cataract., CNS effs., alopec., GI disturbs., precipitat.of ac. gout.  Side effects: Skin erupt., fev., chills, bld.dyscras., arthralg., vasculit.,
   signfic.CV event risk fact., incr. thrombot.event (MI/stroke) risk incr.  Special precautions: Adeq.fluid intake to maint.urin.vol.above   Stev.John.syndr., tox.necrolys., headache, drowsin., alopec., GI dis-
   with high dos. & long.durat.ther., re-eval.treatm.reg., not a substit.   2 L, ren.impairm., xanth. stone format.in childr.with Lesch Nyhan   turbs., vertigo, periph. neurit., gastric irrit., cataract.format., xanthine
   for for aspirin in CV prophylax., do not discont. anti-platelet ther.&   syndr.which may be minim.by urine alkalinsat.& incr.dly.fluid intake.  stone format.in Lesch-Nyhan syndr.
   consid.such ther.if pt. at risk, no evid.that concom.aspirin mitig.incr.  Drug interactions: Inhibits metabol.of mercaptopurine, competes   Special precautions: Not for ac.gout attck treatm., do not admin.
   in ser. thrombot.event risk, ischaem. heart dis.hist., incr. risk of skin   with chlorpropamide for ren.tubul.excret. prolong. chlorpropam.hy-  with concom. chlorpropamide, prolong.hypoglycaem.act.of chlorpro-
   reacts.in pres.of allergy hist., discont. at 1  signs of skin rash/mucos.  poglycaem.act.if ren. funct.poor.  pamide in imp.ren.funct., adeq.fluid intake for dly.urin.output &gt;2L, ren.
                    st
   les./any other hypersens.sign, mild.to mod.hepat.insuffic., elderly, risk   ASPEN COLCHICINE, (Aspen Pharmacare: Pharma) Phar-  impairm., concom. thiaz. diuret., alkalinisat.of urine to minim.poss.
   of GI complicat.with NSAID’s, other concom. NSAID’s/aspirin, prior   macare [P/S]  xanthine stone format., cont.lact.
   GI dis hist., concom. acetylsalic. acid even at low dos.incr.GI advers.   Colchicine.  Drug interactions: Inhib.inactivat.of mercaptopurine, incr.toxic.of
   eff. risk, monit.where S&S of liv.dis. develop & discont.if LFT persist.  Indications: Emerg.ac.gout attacks.  cyclophosphamide & other neo-plast.meds., theophyll.& other xan-
   abnorm., may mask. sympts.of inflam./infect., std.INR value monit.   (S2) TABS. C822.  thine clear.reduc., competit.in ren.tubule for chlorpropamide excret.
   in pts.receiv.warfar., monit.methotrex.relat. toxic.at dos.great.than   715271-009: 0,5 mg, 12, R51,82  SANDOZ ALLOPURINOL 100, 300, Sandoz [P/S]
   90 mg dly., avoid concom. aspir dos.above those for CV prophylax.,   (S2) DS TABS. 41/3.3/0260
   consid. rifampic. interact., incr.EE & conjug.oestrog.expos. poss. incr.  722289-001: 1 mg, 6, R27,29  Allopurinol
                                                              Indications: Gout, hyperuricaem.assoc.with leukaem./ result.from
   OC & HRT assoc.advers.eff.in women at risk, concom.drugs metabol.  Dosage: Ac.gout: Init: 0,5-1 mg then 0,5 mg 2 hrly. till relief obt./
   by human sulfotransferase (eg. oral salbutamol & minoxidil), monit.   GI sympts pres. Max.tot.dly.dos: 6 mg. Min.3 days but pref.7 days   radiother./use of antineoplast. meds./dur.thiazide diuret.treatm.
                                                              (S3) TABS, P/3.3/180, 181
   pt.at high risk of digox.toxic., lact.intol., monit. ren.funct.with con-  to elapse betw.cours.  738778-036: 100 mg, 30, R21,80
   com.ciclospor./tacrolim.     Contraindications: Pts.undergo.haemodialys., sev.ren.impaim.,   738786-004: 300 mg, 30, R66,12
   Drug interactions: Nephrotox.of cyclosporin & tacrolimus poss.  concom.P-gp/potent CYP3A4 inhibit., myelosupress., leucopen.,   Dosage: Admin.aft.meals. Maint.dly.urin.vol.&gt;2 lit. with suffic.
   enchanc., incr.prothromb.time with warfar., AUC decr.with rifampic,   granulocytopen., thrombocytopen., aplast.anaem., pregn.  fluid intake.
   methotrex. plasma conc.poss.incr., antihypetens.eff.of ACE inhibit./   Side effects: Bone marr.depress.with agranulocytos./ thrombocyto-  Adults: 2-10 mg/kg bm/day. Init: 50 mg 2x/day. Incr.dos.as requir.up
   angiotensin II antagon.& diuret.poss. dimin., in ren.impairm.ren.funct.  pen./aplast.anaem./ leucopen.& neutropen., periph.neurit., hypotens.,   to 200-400 mg/day in div.dos or sngl.dos. Sev.gout up to 600 mg dly.
   poss.furth. deterior. with concom.ACE inhibit./angiotensin II antagon.,   GI disturbs., throat burn., GI haemorrh., hepat. damage, alopec., skin   Max.dos: 800 mg/day.
   plasma Li lev.poss.incr., steady state AUC of OC ethinyl estradiol &   rash/burn., urticar., morbilliform erupt., myopathy, rhabdomyolys., ren.   Childr.und.15 yrs: Init.8 mg/kg bm.dly., incr.up to 20 mg/kg dly. Titr.
   HRT conjug.oestrog. incr. with dos.of 120 mg, eff.of furosemide &   damage & dehydrat.with large dos., azoosperm.  dos.acc.to bld.lev.
   thiazide poss.reduc., C max of digox.incr., AUC incr. by ketoconazole   Special precautions: Fatal overdos.report., keep away from chil-  Contraindications: Sev.hepat./ren.disords., ac. gout attack, childr.,
   (potent CYP3A4 inhibit.).    dr., elderly & debilitat.who may be suscept.to cumulat.toxic., card./  lactat.(except those with malign.), safety in pregn.not est.
   RAYZON, Pfizer [P/S] &       hepat./ren.& GI dis., monit.for toxic., myotoxic.incl.rhabdomyolys.   Side effects: Stomatit., allerg.dermatit., skin reacts. incl.erythema
   Parecoxib                    poss. esp.in combinat.with meds.known to cause this eff., INR monit.  multiforme, loosen.of fingernails, Stev.-John.syndr., tox.epiderm.
   Indications: Short-term managem.of post-op.pain incl.hip replacem.  with oral anticoag.& poss. dos. modificat.dur.& aft.treatm., advise pts.  necrolys., alopec., macul.changes & furunculos., gouty arthrit.at-
   surg.for up to 48 hrs.       to report musc. pain/weakn., lactat.as excret.in breast milk, do not   tacks, musc.pain, depress., CNS effs., periph.neurit., paralys., par-
   (S3) POWD.FOR INJ, 36/2.9/0120, Solv: 36/34/0122  use to treat pain from other caus., cont.lact.  aesthes., neuropathy, diabet.mellit., bld.dyscras., steatorrhoea,
   700838-001: 40 mg, 5 vials.+solv., R457,08  Drug interactions: Incr.bld.conc.& toxicity potent. with P-glyco-  hepatotoxic., hepatomegaly, hepat. necros., granulomat., hepatit.,
   Dosage: Admin.IV/IM. IV bolus may be admin. rapidly direct.into   prot./strong CYP3A4 inhibit., myopathy & rhabdomyolis.report.with   abnorm.liv tests, headache, hypersens.vasculit., hypertens., oed.,
   vein/existing IV line. Analges. onset 7-14 mins.& peak eff.within 2 hrs.   statins./fibrates/ ciclospor.& digox., incr.risk of GI disords.& incr. bld.  GI disturbs., haematur., xanthine ren.calcul., xanthine deposit. ren./
   Analges. durat.7-24 hrs. aft.sngl.dos. Transf.to altern.oral ther.when   uric acid conc.with alchol, incr.GI sympts.& bld.disords.with NSAID’s,   urin.disords., ren.urate stone impact., vis. disords., cataracts, impot.,
   clinic.indic. Admin.low.effect.dos.for short.durat.poss.  effs.of oral anticoag. incr., leucopen.& thrombocytopen.effs.poss.   asthen., hypersens. reacts.
   Recomm.dos: Init.40 mg IV/IM, follow.by 20 mg or 40 mg 6-12 hrly.   intens. with concurr./recent meds caus.same effs., addit.bone marr.  Special precautions: Mobilisat.of urate deposit. poss.result in
   Max.dly dos. 80 mg. Concom. opioid use: Optim.eff.is achiev.when   depress.effs.of bone marr.depress. /radiat.ther., vit.B12 absorpt.imp.,   exacerbat.of attacks of gouty arthrit., in ac.gouty attacks treat first
   Rayzon admin.at end of hip replacem.surg.at a fix.time interv.i.e   activ.poss. interfer. with from incr.ser.uric.acid from thiazide diuret.  with colchicine/ indomethacin, concurr.Fe admin.not recomm.in
   12 hrly. prior to opioid admin.  COLCHICINE HOUDE, Cipla Medpro [P/S]  haemochromatos.pts., monit prothromb.activ.in pts. receiv.concom.
   Contraindications: Sulphonamide hypersens. hist., bronchosp.,   Colchicine.  coumar.anticoags., extra vigilance necess.to recogn.enhanc.tox.effs
   ac.rhinit., nas.polyps, angioed., urticar./allerg.-type reacts.precipit.  Indications: Emergency ac.gout.attacks.  with concom. adenine arabinoside., distrib.in breast milk, ren.fail.,
   by acetylsalisal. acid or NSAID’s incl.other COX-2 specif. inhibit.,   (S2) TABS. C665.  discont.immed.if skin reacts.occur, assess exist.urate & urin.acid
   sev.ren./hepat.impairm., post-op & peri-op. analges. in coron.artery   715298-004: 1 mg, 6, R28,08  ser.lev.bef.institut. cytotox.ther., correct hyperuricaem.& /hyperuri-
   bypass surg., est.ischaem heart dis. and/or cerebrovasc.dis.& periph.   Dosage: 1 tab immed. then ½ tab.2 hrly till pain reliev.or vomit.&   cosur. prior to start cytotox.treatm., adeq. hydrat. to maint.max.diures.
   arter. dis., pregn.& lactat., childr.und.18 yrs.  diarrh. interven. Max.tot.treatm.course: 6 mg.  Drug interactions: Inhibits metab.of azathioprin & 6-mercaptopu-
   Side effects: CV/cerebrovasc./GI events/cutan. reacts.which may   Contraindications: Pregn., sev.ren./ hepat. insuff., concom.mac-  rine, uricosur.meds.may reduc. therapeut. activ., prolong.hypogly-
   be fatal, abnorm.stern.serous wound drain., wound infect., post-op   rolide antibiot./pristinamycin, galact.intol., Lapp lact.defic., gluc.-  caem.act.of chlorpropamide in imp.ren.funct., interfer.with hepat.
   anaem., thrombocytopaen., hypokalaem., hyperglycaem., agitat., in-  galact. malabsorpt. syndr., sucrase/isomalt. defic.  inactiv.of oral anticoags., plasma half life of adenine orabinoside
   somn., hypoaesthes., dizzin., bradycard., fluid retent., periph. oed., ag-  Side effects: Bld.dyscras., revers.neuromyopath. disords./azoo-  incr., alcoh./diazox./ mecamylam. or pyrazinam.poss.incr.ser.uric
   grav. hypertens., dysrhythm., hypo-/hypertens., palpitat., tachycard.,   sperm., N&V, abdom.pain, ren.& hepat. damage/dehydr./hypotens./  acid conc., poss.incr.potent.bone marrow depress.with concurr.
   CCF, pharyngit., resp.insuffic., GI disturbs. incl. upper GI perforat./  profuse diarrh. & poss.GI haemorrh.with large dos., skin reacts. incl.  cyclosphospham.& poss.other antineoplast. agents, incr.poss.of
                                                              allopurin.-induc. xanthine kidn.stone format.with urin.acidifiers.,
   ulc.or bleeds, alveol.osteit., skin reacts.incl.exfoliat. dermatit./Stev.  morbillif.erupt., alopec.aft.prolong.treatm., rhabdomyolys.
   John.syndr./ tox.epiderm.necrolys., ecchymos., incr.sweat., back pain,   Special precautions: Reduc./discont.at signs of GI disturbs as   theophyll./aminophyll or oxytriphyll.clear.poss. decr., concurr.cyclo-
   arthralg., oligur., asthen., earache, loc. reacts., ren.fail., hypersens.  freq.1 st  signs of toxic., card./hepat./ ren./ GI dis., elderly/debilit.pts.,   spor.decr.cyclospor.metabol.
   reacts. incl.anaphylax. & angioed.  do not exceed dos., concom. oral anticoag./ciclosporin, monit. esp.
   Special precautions: CV risk fact., high.dos./ prolong.durat., not a   init.with concom. HMG-CoA reduct.inhibits., teratogen.in animals,
   substit.for aspir.for CV prophylax., no evid.that concom.aspir.will miti-  pass.into breast milk, toxic.signs, avoid in bld.disords., creat.clear.   4.3   Topical agents
   gate incr.risk of assoc.ser.CV thromboembol.events, sev. ren.impairm.,   assessm.bef.init.ther. esp.in elderly, concom. treatm.weaken.ren./
   mod.hepat.impairm., correct dehydrat.bef.init.ther., comprom.card.  hepat.funct. &/introd.bone marrow/musc.toxic.assessm.bef.init.ther.
   funct.or other condits. predispos.to/worsen.by fluid retent., pre-exist.  Drug interactions: Incr.oral anticoag.eff., incr. neuromusc. eff.with   ARTHRU-DERM, (Activo) MeyerZall [P/S]
   CHF/hypertens., discont.at 1  appear.of skin rash/other hypersens.  ciclosporin, incr.musc.effs. esp. rhabdomyolys. with HMG-CoA reduct.   Diclofenac sod.
               st
   reacts., fev.poss.mask., monit.incis.for infect.signs, GI perforat./ulc.  inhibits., incr.ser.uric lev.with thiazide diurets., poss.Vit. B 12 absorpt.  Indications: Loc.traumat.inflam.& pain.
   or bleed. hist., elderly partic.fem.pts.weigh.less than 50 kg, monit.   interfer., poss.incr.colchicine effs.somet.potent.fatal with macrolide   (S1) LOT, 31/3.1/0383. 1,0 g/100 g.
   ren.funct.with ciclosp.& tacrolimus, concom.Li, monit. anticoag.ther.,   antibiot.& pristinamycin.  852201-001: 1 %, 50 g, R52,64
   concom.ACE inhibits., reduc.dos.with concom.fluconazole, use with   Dosage: Apply to intact skin 2-3xdly.
   sterile water/Lact.Ringer’s/ 5% Gluc.in Lact. Ringer’s not recomm.  PROBEN, (Aspen Pharmacare: Pharma) Pharmacare   2-4 g (1-2 fingertips) 3-4xdly.to affect.area. Use low. eff.dos.for
   Drug interactions: Nephrotox.of cyclospor.& tacrolimus incr., poss.  Probenecid.  short.durat
   natriuret.eff.of furosem.& thiaz.reduc., plasma expos.incr.with flucon-  Indications: Reduc.freq.of ac.gout attacks, to prev.format.of new   Contraindications: Hypersens.to aspir.& other NSAID’s, diffuse
   azole & ketoconazole, Li clear. decr., incr.bleed.complicat. risk with   tophi & reduc.those pres.  skin dis./burns/ulc., porphyr., safety & effic.in childr.nor est., safety
   warfar., ACE inhibits. antihypertens.eff. dimin. with Rayzon inhibit.  (S3) TABS. C875.  in pregn.not est.
   See also MDR page 644.       757152-007: 500 mg, 100, R473,37  Side effects: Skin itch./redden./smart./rash, poss.syst.S/E with pro-
                                Dosage: ½ tab. 2xdly. x1 wk., then 1 tab. 2xdly. May be grad.incr.to
                                                              long.use incl.headache/ dizzin./tinnit./GI disturbs.incl.bleed., hyper-
                                max. 2 g dly.in 2-4 div.dos.  sens., fev., hepatotoxic., asept.meningit., bronchosp.in asthma pts.,
                                Contraindications: Ren.uric acid calculi, bld. dyscras.  ac.ren.fail., cystit., haematur., interstit. nephrit., nephrot.syndr., skin
   4.2    Anti-gout             Side effects: N&V, headache, sore gums, flush., dizz., urin.freq.,   reacts., bld.dyscras., eye disords.
                                                              Special precautions: Apply to intact surfac., not applied to skin
                                anaem., skin rash., hypersens. react., precipat.of ac.gout attack.
   ADCO-ALLOPURINOL AI Pharm [P/S]  Special precautions: Pept.ulcerat.  wounds/open injur., no cont.with eyes/ muc.membr., not to be
                                Drug interactions: Salicyl.eff.antagon. uricosuric.eff.
                                                              taken by mouth.
   Allopurinol                                                Drug interactions: Rais.Li/digox./methotrex. conc., bioavail.reduc.
   Indications: Prophylact.treatm.of gout & hyperuricaem. assoc.  PURICOS, (Aspen Pharmacare: Pharma ) Pharmacare [P/S]  by aspir.& vice versa with concom. use.
   with other condits., hyperuricaem. assoc.with leukaem/ radiother./   Allopurinol.
   antineoplast./diuret.ther    Indications: Gout, hyperuricaem.assoc with other condits.  ELMETACIN, Litha [P/S]
   (S3) TABS. 29/3.3/0229       (S3) TABS. K/3.3/305, L/3.3/257.  Indomethacin
   719128-001: 300 mg, 30, R65,65  758310-005: 100 mg, 100, R90,21  Indications: Pain, inflam.& swell.assoc.with degen. joint disords.,
   Dosage: Intermitt.gout treatm: Init. 50 mg 2x/day incr.as reqd.to   758310-013: 100 mg, 500, R451,04  periarticul.rheumat.disords., sports & accident.injur.
   200-400 mg/ day in div.dos. Sev.cases: up to 600 mg may be necess.  758329-008: 300 mg, 30, R74,71  (S1) SOL, T/3.1/173
   Hyperuricaem.assoc.with leukaemia: Init. 200 mg 3xdly 2-3   758329-016: 300 mg, 250, R622,57  887982-007: 10 mg/g, 50 ml, R103,34
   days bef.radiother./ antineoplast. agent adjust to maint.of usually   Dosage: Gout: Init.50 mg 2xdly. Incr.if reqd.to 200-400 mg dly in   Dosage: Spray 2 ml (approx.25 sprays) on affect. area 3-5xdly. Max:
   300-400 mg dly. Childr: Init. 8 mg/ kg bm dly.  div.dos. Max.600 mg dly.   25 ml/day = 200 mg indomethacin.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page106.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page102.html">102</a>&nbsp;&nbsp;&nbsp;<a href="page103.html">103</a>&nbsp;&nbsp;&nbsp;<a href="page104.html">104</a>&nbsp;&nbsp;&nbsp;<a href="page105.html">105</a>&nbsp;&nbsp;&nbsp;<a href="page106.html">106</a>&nbsp;&nbsp;&nbsp;<a href="page107.html">107</a>&nbsp;&nbsp;&nbsp;<a href="page108.html">108</a>&nbsp;&nbsp;&nbsp;<a href="page109.html">109</a>&nbsp;&nbsp;&nbsp;<a href="page110.html">110</a>&nbsp;&nbsp;&nbsp;<a href="page111.html">111</a>&nbsp;&nbsp;&nbsp;<a href="page112.html">112</a>
             </td>
             <td width="35%"><a href="page108.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page108.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
